Clinical Trials Logo

Filter by:
NCT ID: NCT03388528 Completed - Clinical trials for Mitochondrial Diseases

Low Residue Diet Study in Mitochondrial Disease

LRD
Start date: September 8, 2017
Phase: N/A
Study type: Interventional

Slow movement of patients guts is referred to as intestinal dysmotility, and is increasingly recognised as a debilitating manifestation of mitochondrial disease both in adults and children. To date, symptoms of slow gut movements have been managed with laxatives and drugs that increase movement of the guts with variable results. A low residue diet is a form of low fibre diet (<10g fibre per day) that is used to minimise symptoms of poor movement of the guts. This reduces fecal volume and bulk, and hence gut workload, ensuring limited bowel activity and colonic rest. It has been shown to be well accepted in other conditions associated with slow gut movements. However, its role in patients with mitochondrial disease is unknown. The investigators are particularly interested in: - Does a low residue diet (low fibre) cause a change in the number of stools per week and stool consistency? - Is a low residue diet tolerated well and easy to comply with? - Does a low residue diet reduce gut symptoms of abdominal pain, bloating, and constipation? - Does a low residue diet improve quality of life and disease burden? - Does a low residue diet affect the bacteria in the gut? - Can we prove by X-ray that movement of food through the gut is slowed in patients with mitochondrial disease, and whether a low residue diet alters the speed of movement of food through the gut? - Can a low residue diet change patients physical activity levels? - Does a low reside diet change dietary patterns and food intake? - Does a low residue diet alter anthropometrics, such as weight, body mass index and waist to hit ratio? - Can a low residue diet improve kidney and liver function and lipid profile in blood samples? The investigators hope that by looking at these areas that a low residue diet may be able to improve patients slow gut movements, health, quality of life and disease burden.

NCT ID: NCT03388047 Completed - Clinical trials for Esophageal Neoplasms

Feasibility of Multi-Spectral Endoscopic Imaging for Detection of Early Neoplasia in Barrett's Oesophagus

MuSE
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Multispectral imaging represents an exciting new field of investigation in endoscopic research. Multispectral imaging uses a specialised camera to detect multiple colours, allowing us to build a rough spectrum from each point in our image. It is widely reported that these spectra are different for different tissue types, but this is difficult to study ex vivo since de-oxygenation of the blood and decay of the tissue change these spectra considerably. The investigators have therefore designed this study to asses the different multispectral imaging spectra of Barrett's Oesophagus, which we believe might be utilised as a method to detect dysplasia in the future.

NCT ID: NCT03387410 Completed - Ureter Injury Clinical Trials

Ureter Identification With IRDye 800BK

Start date: April 6, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2a study, second in-man utilising IRDye800BK in ureteric identification using fluorescence throughout abdominal surgery. Study is open label, non-randomised prospective study.

NCT ID: NCT03385564 Completed - Lupus Nephritis Clinical Trials

An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis

Start date: January 9, 2018
Phase: Phase 2
Study type: Interventional

The main objectives of this trial are to evaluate the long term efficacy and safety of different doses of BI 655064 versus placebo as add-on therapy to Standard of Care (SOC) during maintenance therapy for lupus nephritis.

NCT ID: NCT03384966 Completed - Clinical trials for Stable Coronary Artery Disease

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

Start date: January 24, 2018
Phase: Phase 2
Study type: Interventional

The goal of this study is to find out if a drug called selatogrel (ACT-246475) can prevent platelets from binding together when administered by an injection under the skin in the thigh or in the belly. Another goal is to know how fast and for how long selatogrel (ACT-246475) works and if there is a difference if the drug is injected in the thigh or in the belly. This study will also help to find out more about the safety of this new drug.

NCT ID: NCT03384940 Completed - Colorectal Neoplasm Clinical Trials

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Start date: February 23, 2018
Phase: Phase 2
Study type: Interventional

The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.

NCT ID: NCT03384654 Completed - Clinical trials for Precursor Cell Lymphoblastic Leukemia-Lymphoma

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Start date: May 14, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL) and T-cell ALL/LL as measured by the complete response (CR) rate.

NCT ID: NCT03384628 Completed - Myopia Clinical Trials

An Evaluation Of The Fitting Success Rate Of Senofilcon A Soft Contact Lenses In Three Designs.

Start date: January 26, 2018
Phase: N/A
Study type: Interventional

This study will compare the on-eye fitting characteristics of three types of contact lenses. Each lens pair will be worn for 30 to 45 minutes before assessment and the results will be compared to mathematically calculated fitting characteristics.

NCT ID: NCT03384186 Completed - Healthy Clinical Trials

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

Start date: December 1, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study was to evaluate and compare the plasma pharmacokinetic profiles of ACH-0144471 (danicopan) in healthy participants after administration of single oral doses of modified release prototype formulations.

NCT ID: NCT03383809 Completed - Healthy Clinical Trials

Impact of Non Digestible Carbohydrate on Production of Phenolic Acids From Strawberry Juice

Start date: April 28, 2017
Phase: N/A
Study type: Interventional

This is an acute human bioavailability study in self-reported healthy participants aged 20-70 years old. We hypothesize that combination of dietary polyphenolics and non-digestible carbohydrates (NDC) will increase the production of phenolic acids by bacteria in the human colon and these will be detected in urine. Participants will attend for three arms in a randomised order: Strawberry juice (a high polyphenol food), Inulin (NDC) or Mixture of strawberry juice and inulin.